SLC2A1 and cancer: As mentioned above, NBR2 deficiency renders cancer cells more sensitive to phenformin through the inhibition of GLUT1 expression, suggesting that the NBR2–GLUT1 axis may serve as an adaptive response for phenformin treatment (71, 80).